Clinical trial · Observational
European Physician Survey of EGFR Inhibitor Prescribing Patterns
Survey of Oncologists in Europe to Evaluate Their Knowledge of KRAS Testing
NCT01652833CI-TRIAL-00060762completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To ensure the appropriate administration of Vectibix for the treatment of mCRC with wild-type KRAS in real-world practice, it is important to understand the awareness of practicing oncologists regarding the correct indication and appropriate administration of Vectibix. It is also critical to monitor changes in oncologists' awareness and practice between the different rounds of the study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Physician Survey | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Round 1
- description
- survey of 150 oncologists
- interventionNames
- Other: Physician Survey
- label
- Round 2
- description
- survey of 150 oncologists approximately 12 months after round 1
- interventionNames
- Other: Physician Survey
- label
- Round 3
- description
- survey of 150 oncologists approximately 24 months after round 1
- interventionNames
- Other: Physician Survey
Primary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Physician Inclusion Criteria: * Must be a practicing oncology specialist * Must treat at least 3 new or continuing patients with metastatic colorectal cancer in the last quarter * Must have prescribed Vectibix within the last 6 months to metastatic colorectal cancer patients Exclusion Criteria: * Must not have taken part in this study previously * Must not have participated in Amgen study number 20101120.
References
Publications (0)
Data not yet available
No reference posted for this study.